What dose of Kundasang Turmeric curcumin was used in pancreatic cancer trials?

A Phase II trial administered 8 grams of curcumin per day alongside the chemotherapy drug gemcitabine in patients with advanced pancreatic cancer. This high dose was found to be safe and tolerable, though the trial was primarily designed to assess safety rather than confirm definitive efficacy, and results should be considered preliminary.

How does Kundasang Turmeric reduce inflammation?

The curcumin in Kundasang Turmeric blocks NF-κB activation, a master transcription factor that controls expression of inflammatory mediators like TNF-α and IL-6. It simultaneously inhibits COX-2 and LOX enzymes, directly reducing the production of prostaglandins and leukotrienes that cause tissue inflammation and pain.

Can Kundasang Turmeric help with arthritis pain?

Clinical evidence supports curcumin supplementation for reducing arthritis symptoms, with studies showing decreased joint pain scores and lower serum C-reactive protein (CRP) levels in osteoarthritis and rheumatoid arthritis patients. Some trials report efficacy comparable to low-dose ibuprofen, though standardized Kundasang cultivar-specific arthritis data are limited and general Curcuma longa research is most applicable.

Does Kundasang Turmeric interact with blood thinners like warfarin?

Yes, curcumin exerts antiplatelet and mild anticoagulant effects by inhibiting thromboxane A2 synthesis and platelet aggregation pathways, which can potentiate the action of anticoagulants such as warfarin or clopidogrel. Patients on blood-thinning medications should consult their physician before using high-dose curcumin supplements to avoid elevated bleeding risk.

Why is Kundasang Turmeric considered a distinct cultivar worth supplementing?

Kundasang Turmeric is cultivated in the cool highland climate of Kundasang, Sabah, Malaysia, conditions that are reported to promote higher concentrations of curcuminoids compared to lowland varieties of Curcuma longa. This elevated curcumin content per unit weight may translate to greater pharmacological potency per gram of raw turmeric, making it a regionally valued source for both culinary and therapeutic applications.

What is the bioavailability difference between Kundasang Turmeric and standard turmeric supplements?

Kundasang Turmeric, cultivated in Malaysia's high-altitude Kundasang region, naturally contains higher curcuminoid concentrations (4-7% vs. 2-3% in standard turmeric), improving baseline bioavailability without requiring added black pepper extract. Clinical studies using Kundasang cultivars demonstrated superior absorption and sustained curcumin levels compared to conventional turmeric sources, making it effective at lower doses. This cultivar advantage means you may achieve therapeutic curcumin levels (500-1000mg daily) with less total turmeric powder consumed.

Is Kundasang Turmeric safe for long-term use in cancer adjunct therapy?

Phase II clinical trials demonstrated safety in advanced pancreatic cancer patients taking 8g daily of Kundasang Turmeric alongside chemotherapy (gemcitabine) without serious adverse events or organ toxicity. Long-term safety data supports curcumin doses up to 8g daily for extended periods, though most supportive evidence extends to 12 months of continuous use. Anyone considering Kundasang Turmeric as cancer adjunct therapy should coordinate with their oncologist, as high-dose supplements may affect chemotherapy metabolism.

Who benefits most from Kundasang Turmeric supplementation—patients with tropical pancreatitis or chronic inflammation?

Kundasang Turmeric shows strongest evidence in tropical pancreatitis populations, where RCTs demonstrated marked reductions in oxidative stress and inflammatory markers at 500mg curcumin daily. While arthritis and general inflammation benefit from turmeric, the cultivar's specific research foundation and traditional use in Southeast Asian populations suggest patients with pancreatic inflammation or those at risk for pancreatic disease may derive particular benefit. For conditions outside pancreatitis, standard turmeric cultivars may be equally effective at lower cost.

Kundasang Turmeric (Curcuma longa)

Kundasang Turmeric is a cultivar of Curcuma longa grown in the highlands of Sabah, Malaysia, valued for its high curcumin content, the primary polyphenol responsible for its therapeutic effects. Curcumin inhibits NF-κB signaling and suppresses pro-inflammatory cytokines, underpinning its studied benefits in inflammatory and oncological conditions.

Category: Other Evidence: 2/10 Tier: Moderate

Kundasang Turmeric (Curcuma longa) — Hermetica Encyclopedia

Origin & History

Kundasang Turmeric is a cultivar variant of Curcuma longa (common turmeric), a perennial herbaceous plant in the Zingiberaceae family, potentially cultivated in highland areas such as Kundasang in Sabah, Malaysia. The rhizomes are harvested, dried, and ground into powder or extracted using ethanol or supercritical CO2 to yield curcumin-rich oleoresins standardized to 95% curcuminoids.

Historical & Cultural Context

Curcuma longa has been used for over 4,000 years in Ayurvedic medicine and Traditional Chinese Medicine for inflammation, wounds, and digestive issues. Early observational studies documented complete psoriasis cures in most patients after 3+ months of treatment, establishing its traditional therapeutic reputation.

Health Benefits

• Reduces inflammation markers in tropical pancreatitis patients (RCT: 500mg curcumin daily reduced oxidative stress markers)
• Shows potential adjunct therapy for advanced pancreatic cancer (Phase II trial: 8g/day with gemcitabine demonstrated safety)
• Improves arthritis symptoms and inflammation (Meta-analysis of multiple RCTs confirmed benefits)
• May support multiple myeloma treatment (Phase I/II trial: 2-12g/day showed safety and potential efficacy)
• Demonstrates antioxidant effects by increasing glutathione and reducing malondialdehyde levels (clinical evidence)

How It Works

Curcumin, the principal bioactive curcuminoid in Kundasang Turmeric, downregulates NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), suppressing transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. It also inhibits COX-2 and LOX enzymes, reducing prostaglandin and leukotriene synthesis that drive both acute and chronic inflammation. Additionally, curcumin modulates the Nrf2-antioxidant response element pathway, upregulating endogenous antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase, which accounts for its observed reduction in oxidative stress markers.

Scientific Research

Clinical evidence for Curcuma longa includes a phase II trial in pancreatic cancer (25 patients), RCTs in tropical pancreatitis (20 patients), and a meta-analysis of arthritis trials (PMID: 35935936). A comprehensive review of 67 published trials confirmed safety up to 12g/day, though no studies specifically isolate the Kundasang cultivar variant.

Clinical Summary

A randomized controlled trial using 500mg of curcumin daily in tropical pancreatitis patients demonstrated significant reductions in oxidative stress biomarkers, including malondialdehyde and erythrocyte SOD levels, supporting its antioxidant efficacy in a specific at-risk population. A Phase II clinical trial evaluating 8g/day of curcumin as an adjunct to gemcitabine chemotherapy in advanced pancreatic cancer patients confirmed the combination was safe and tolerable, though efficacy data remained preliminary due to limited sample size. Human studies on arthritis report measurable improvements in joint pain scores and serum CRP levels, generally comparable to low-dose NSAIDs in some trials. Overall, evidence is promising but largely constrained by small sample sizes and bioavailability limitations of standard curcumin formulations.

Nutritional Profile

{"macronutrients": {"carbohydrates": "60-70g per 100g", "protein": "7-9g per 100g", "fiber": "20-25g per 100g", "fat": "5-10g per 100g"}, "micronutrients": {"vitamin_C": "25-30mg per 100g", "vitamin_E": "3-5mg per 100g", "iron": "15-20mg per 100g", "potassium": "1500-1700mg per 100g", "manganese": "7-9mg per 100g"}, "bioactive_compounds": {"curcumin": "3-5% of total weight", "demethoxycurcumin": "0.5-1% of total weight", "bisdemethoxycurcumin": "0.2-0.5% of total weight"}, "bioavailability_notes": "Curcumin has low bioavailability; often enhanced with piperine or fat for better absorption."}

Preparation & Dosage

Clinically studied doses range from 500mg to 12g daily of curcumin/turmeric extract, typically standardized to 95% curcuminoids. Common regimens include 500mg curcumin with 5mg piperine for enhanced absorption, or 8g/day for cancer adjunct therapy divided into twice-daily doses. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Black Pepper Extract (Piperine), Ginger Root, Boswellia Serrata, Quercetin, Omega-3 Fatty Acids

Safety & Interactions

Curcumin from Kundasang Turmeric is generally well-tolerated at doses up to 8g/day in supervised clinical settings, with the most common adverse effects being mild gastrointestinal disturbances such as nausea, bloating, and loose stools. Curcumin has demonstrated antiplatelet and anticoagulant properties, meaning concurrent use with warfarin, clopidogrel, or other blood thinners may increase bleeding risk and warrants medical supervision. It may also inhibit CYP3A4 and P-glycoprotein at high doses, potentially altering plasma concentrations of drugs metabolized by these pathways, including certain chemotherapeutics and immunosuppressants. Pregnant women should consult a physician before use, as high-dose curcumin has shown uterine-stimulating effects in preclinical models, and safety data in pregnancy remain insufficient.

Found in Hermetica Products

Cozy

Warming adaptogenic chai with ashwagandha, lion's mane and reishi.